Cipla Ltd.

The US Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) audit at Cipla’s Indore formulations facility from April 2, 2018 till April 13, 2018. This was in the normal course of business. There were no data integrity and/or repeat observations.

The company believes the observations are unlikely to have any material adverse impact and it will submit the response within the stipulated timeframe.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.